Skip to main content
. 2018 Jan 24;7(1):7. doi: 10.1038/s41389-017-0022-6

Fig. 4. EBAG9 interacts with TM9SF1 to regulate migration and EMT in prostate cancer cells.

Fig. 4

a Interaction between EBAG9 and TM9SF1 in 293T cells. Lysate of 293T cells transfected with Flag-EBAG9 and HA-TM9SF1 plasmids was immunoprecipitated with anti-EBAG9, anti-TM9SF1 or control IgG, then subjected to western blot analysis using EBAG9 (left panel) or TM9SF1 (right panel) antibody. Arrows show signals for Flag-EBAG9 and HA-TM9SF1. b Subcellular co-localizatiion of EBAG9 and TM9SF1. HeLa cells were transfected with GFP-TM9SF1 and DsRed-EBAG9, and subjected to fluorescent microscopic examination. Scale bars, 10 μm. c TM9SF1 silencing inhibits LNCaP cell migration. Cells transfected with siRNA targeting TM9SF1 (siTM9SF1 #1) or siControl were seeded on the upper chamber and migrated cells were stained after 48 h. Representative images are shown. Scale bar, 20 μm. Migrated cell numbers were counted in 5 microscopic fields at least. Data are shown as mean ± SD (n = 5). d TM9SF1 modulates EMT-related gene expression in LNCaP cells. qRT-PCR analyses for indicated genes were performed using RNAs prepared from LNCaP cells treated with siTM9SF1 #1 or siControl. e TM9SF1 contributes to cell migration interacting with EBAG9. LNCaP-EBAG9 #4 and LNCaP-Vector #5 cells were transfected with siTM9SF1 #1 or siControl, and cell migration was examined as described above. Data are shown as mean ± SD (n = 5). f TM9SF1 plays a role in EMT-related gene expression along with EBAG9. LNCaP-EBAG9 #4 and LNCaP-Vector #5 cells were transfected with siTM9SF1 #1 or siControl, and SNAI2 mRNA expression was quantified as described. Data are shown as mean ± SD (n = 3). *P < 0.05; **P < 0.01 (two-sided Student’s t-test)